Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.
Michael K.K. Wong
Consultant or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer
Eric Jonasch
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Sumanta Kumar Pal
Consultant or Advisory Role - Novartis
Honoraria - Novartis
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Research Funding - employee of Analysis Group, Inc, which has received consulting fees from Novartis
Peggy L. Lin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Research Funding - employee of Analysis Group, Inc, which has received consulting fees from Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kenneth W. Culver
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey A. Scott
Employment or Leadership Position - Cardinal Health
Stock Ownership - Cardinal Health
Daniel J. George
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; PAREXEL International